Endogenous peptide CBDP1 inhibits clear cell renal cell carcinoma progression by targeting USP5/YTHDF2/TRPM5 axis
Abstract Background: Clear cell renal cell carcinoma (ccRCC) has a high incidence rate and poor prognosis, and currently lacks effective therapies. Recently, peptide-based drugs have shown promise in cancer treatment. In this research, a new endogenous peptide called CBDP1 was discovered in ccRCC an...
| Auteurs principaux: | , , , , , |
|---|---|
| Format: | Article |
| Langue: | English |
| Publié: |
BMC
2025-01-01
|
| Collection: | Journal of Translational Medicine |
| Sujets: | |
| Accès en ligne: | https://doi.org/10.1186/s12967-025-06091-4 |